Marker Therapeutics Inc (MRKR)

[BluMarlin1960]

.9 cents away from another $10 Mill, giving them about 12 million minimum in coffers.

12 Mill cash, best science in the industry, low float, Possible Fast Track, IND, Orphan Status update, news imminent on full line data, news on completion of securing the licensing, new Collaboration update, entry into Phase 11 in at least two indications possibly more, update on Polystart.

Any of these catalyst’s may move stock into the $1.50 range, most likely will be driven into the $2/$3 range if most or all come to fruition, company will be debt free, and have the best in class for exceptional low cost to produce. Glynn hinted that they will be close to a commercial product by year end.

More than enough money now to complete Phase 11, on possibly both indications, as MAYO has already has obtained partial funding...multiple multi-billion dollar markets.

As we move into the $1.50/$2 range expect news of the up-list, which could drive us much higher, all of these drivers possible within the next 3 months.

Tapimmune’s game plan looks quite flawless at this point, positioning them for what most would expect to be multiple buyout candidates, which has been my premise from the outset.

DART most likely to put the brakes on share flow moving forward, making the rise in share price accelerated.

GLTA Fundamentals still look great.

BLU